Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
Protocol ID
ARST1431
Disease (Sub Disease)
Rhabdomyosarcoma
Diagnosis Stage
New diagnosis
Location
NSW, QLD, WA, NZ
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
under 40 years of age
International registry ID's
NCT02567435
| Study Title | A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) |
|---|---|
| Protocol ID | ARST1431 |
| Disease (Sub Disease) | Rhabdomyosarcoma |
| Diagnosis Stage | New diagnosis |
| Location | NSW / QLD / WA / NZ |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02567435 |
| Trial Status | Open |
| Trial Open Date | 09/12/2016 |
| Sites | The Children's Hospital at Westmead / John Hunter Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Christchurch Hospital / Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | under 40 years of age |
| International registry ID's | NCT02567435 |